Clinical trial
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in…
NCT00320489 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00320489 |
|---|---|
| Title | Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia |
| Official title | A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | olanzapine, olanzapine pamoate depot |
| Enrollment | 524 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | May 3, 2006 |
| Last update posted | Jan 23, 2012 |
| Countries | Argentina, Brazil, Canada, France, Greece, Portugal, Puerto Rico, Romania, Slovakia, Spain, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: